Современное представление о химиоиндуцированной полинейропатии (обзор литературы)

Обложка

Цитировать

Полный текст

Аннотация

Обзор посвящен химиоиндуцированной полинейропатии – частому нежелательному явлению терапии злокачественных новообразований, которое снижает качество жизни пациентов и может приводить к изменению тактики ведения: модификации дозы, отсрочке введения препарата и даже полному прекращению лечения, что ставит под угрозу жизнь пациента. В основе химиоиндуцированного повреждающего действия периферических нервов лежат разные механизмы в зависимости от вида цитотоксического агента. Наиболее нейротоксичными являются препараты платины, таксаны, алкалоиды барвинка, бортезомиб и талидомид. В результате нейротоксического воздействия возникает повреждение тонких и толстых волокон периферических нервов. Однако до сих пор остается загадкой, почему у одного пациента развиваются проявления нейротоксичности, а у другого – нет. Перед современным медицинским сообществом по-прежнему остро стоит вопрос изучения механизмов развития, факторов риска, а также поиска биомаркеров и разработки методов профилактики, лечения химиоиндуцированной полинейропатии. Обобщены результаты исследований по механизму возникновения, клинике, диагностике, профилактике и лечению химиоиндуцированных полинейропатий.

Об авторах

О. А. Тихонова

ФГАОУ ВО «Балтийский федеральный университет им. Иммануила Канта»

Автор, ответственный за переписку.
Email: offelia78@mail.ru
ORCID iD: 0000-0002-1796-0193

Ольга Алексеевна Тихонова,

236016 Калининград, ул. Александра Невского, 14

Россия

Д. С. Дружинин

ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава России

Email: fake@neicon.ru
ORCID iD: 0000-0002-6244-0867

150000 Ярославль, ул. Революционная, 5

Россия

А. М. Тынтерова

ФГАОУ ВО «Балтийский федеральный университет им. Иммануила Канта»

Email: fake@neicon.ru
ORCID iD: 0000-0003-1743-4713

236016 Калининград, ул. Александра Невского, 14

Россия

И. В. Реверчук

ФГАОУ ВО «Балтийский федеральный университет им. Иммануила Канта»

Email: fake@neicon.ru
ORCID iD: 0000-0002-3498-9094

236016 Калининград, ул. Александра Невского, 14

Россия

Список литературы

  1. Miller K.D., Nogueira L., Mariotto A. B. et al. Cancer treatment and survivorship statistics, 2019. Cancer J Clin 2019;69(5):363–85. doi: 10.3322/caac.21565
  2. Molassiotis A., Cheng H. L., Lopez V. et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019;19(1):1–19. doi: 10.1186/s12885-019-5302-4
  3. Banach M., Juranek J.K., Zygulska A.L. Chemotherapy-induced neuropathies – a growing problem for patients and health care providers. Brain Behav 2017;7(1):e00558. doi: 10.1002/brb3.558
  4. Cavaletti G., Alberti P., Argyriou A.A. et al. Chemotherapy-induced peripheral neurotoxicity: a multifaceted, still unsolved issue. J Periph Nerv Sys 2019;24:S6–S12. doi: 10.1111/jns.12337
  5. Seretny M., Currie G.L., Sena E.S., et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155(12):2461–70. doi: 10.1016/j.pain.2014.09.020
  6. Jordan B., Jahn F., Sauer S. et al. Prevention and management of chemotherapy-induced polyneuropathy. Breast Care 2019;14(2): 79–84. doi: 10.1159/000499599
  7. Ghoreishi Z., Keshavarz S., Asghari Jafarabadi M. et al. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer 2018;18(1):1–6. doi: 10.1186/s12885-018-4869-5
  8. Hershman D.L., Till C., Wright J.D. et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol 2016;34(25):3014. doi: 10.1200/JCO.2015.66.2346
  9. Saito Y., Takekuma Y., Shinagawa N. et al. Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer. Sup Care Cancer 2022;30(5):4081–8. doi: 10.1007/s00520-021-06757-x
  10. Shah A., Hoffman E.M., Mauermann M.L. et al. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry 2018;89(6):636–41. doi: 10.1136/jnnp-2017-317215
  11. Inada M., Sato M., Morita S. et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 2010;48(11):729–34. doi: 10.5414/cpp48729
  12. Apellániz-Ruiz M., Lee M.Y., Sánchez-Barroso L. et al. Wholeexome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy CYP3A4 variants and paclitaxel dose-limiting neuropathy. Clin Cancer Res 2015;21(2):322–8. doi: 10.1158/1078-0432.CCR-14-1758
  13. Nakamura T., Hashiguchi A., Suzuki S. et al. Vincristine exacerbates asymptomatic Charcot–Marie–Tooth disease with a novel EGR2 mutation. Neurogenetics 2012;13(1):77–82. doi: 10.1007/s10048-012-0313-1
  14. Guijosa A., Freyria A., Espinosa-Fernandez J.R. et al. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis. Clin Transl Sci 2022;15(10):2403–36. doi: 10.1111/cts.13370
  15. Argyriou A.A., Bruna J., Genazzani A.A. et al. Chemotherapyinduced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol 2017;13(8):492–504. doi: 10.1038/nrneurol.2017.88
  16. Zajączkowska R., Kocot-Kępska M., Leppert W. et al. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 2019;20(6):1451. doi: 10.3390/ijms20061451
  17. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33(1):9–23. doi: 10.1016/j.ctrv.2006.09.006
  18. Dasari S., Tchounwou P.B. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014;740:364–78. doi: 10.1016/j.ejphar.2014.07.025
  19. Was H., Borkowska A., Bagues A. et al. Mechanisms of chemotherapy-induced neurotoxicity. Front Pharmacol 2022;13:750507. doi: 10.3389/fphar.2022.750507
  20. Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxeland oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011;232(2):154–61. doi: 10.3389/fphar.2022.750507
  21. Chukyo A., Chiba T., Kambe T. et al. Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity. Neuropeptides 2018;67:95–101. doi: 10.1016/j.npep.2017.12.002
  22. Warwick R., Hanani M. The contribution of satellite glial cells to chemotherapy-induced neuropathic pain. Eur J Pain 2013;17(4):571–80. doi: 10.1002/j.1532-2149.2012.00219.x
  23. Schmitt L.I., Leo M., Kutritz A. et al. Activation and functional modulation of satellite glial cells by oxaliplatin lead to hyperexcitability of sensory neurons in vitro. Mol Cell Neurosci 2020;105:103499. doi: 10.1016/j.mcn.2020.103499
  24. Makker P.G., Duffy S.S., Lees J.G. et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PloS One 2017;12(1):e0170814. doi: 10.1371/journal.pone.0170814
  25. Robinson C.R., Zhang H., Dougherty P.M. Astrocytes, but not microglia, are activated in oxaliplatin and bortezomibinduced peripheral neuropathy in the rat. Neurosci 2014;274:308–17. doi: 10.1016/j.neuroscience.2014.05.051
  26. Velasco R., Bruna J. Taxane-induced peripheral neurotoxicity. Toxics 2015;3(2):152–69. doi: 10.3390/toxics3020152
  27. Xiao W.H., Zheng H., Zheng F.Y. et al. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neurosci 2011;199:461–9. doi: 10.1016/j.neuroscience.2011.10.010
  28. Loprinzi C.L., Reeves B.N., Dakhil S.R. et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011;29(11):1472. doi: 10.1200/JCO.2010.33.0308
  29. Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J Periph Nerv Sys 2008;13(1):27–46. doi: 10.1111/j.1529-8027.2008.00156.x
  30. Triarico S., Romano A., Attinà G. et al. Vincristine-induced peripheral neuropathy (VIPN) in pediatric tumors: Mechanisms, risk factors, strategies of prevention and treatment. Int J Mol Sci 2021;22(8):4112. doi: 10.3390/ijms22084112
  31. Amirkhanloo F., Karimi G., Yousefi-Manesh H. et al. The protective effect of modafinil on vincristine-induced peripheral neuropathy in rats: A possible role for TRPA1 receptors. Basic Clin Pharmacol Toxicol 2020;127(5):405–18. doi: 10.1111/bcpt.13454
  32. Liang Y., Ma S., Zhang Y. et al. IL-1β and TLR4 signaling are involved in the aggravated murine acute graft-versus-host disease caused by delayed bortezomib administration. J Immunol 2014;192(3):1277–85. doi: 10.4049/jimmunol.1203428
  33. Stockstill K., Doyle T.M., Yan X. et al. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J Exp Med 2018;215(5):1301–13. doi: 10.1084/jem.20170584
  34. Argyriou A.A., Iconomou G., Kalofonos H.P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112(5):1593–9. doi: 10.1182/blood-2008-04-149385
  35. Mohty B., El-Cheikh J., Yakoub-Agha I. et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010;95(2):311. doi: 10.3324/haematol.2009.012674
  36. Ventzel L., Jensen A.B., Jensen A.R. et al. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 2016;157(3):560–8. doi: 10.1097/j.pain.0000000000000404
  37. Ta L.E., Espeset L., Podratz J. et al. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum – DNA binding. Neurotoxicology 2006;27(6):992–1002. doi: 10.1016/j.neuro.2006.04.010
  38. Lucchetta M., Lonardi S., Bergamo F. et al. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemother Pharmacol 2012;70(6):899–902. doi: 10.1007/s00280-012-2006-8
  39. Brewer J.R., Morrison G., Dolan M.E. et al. Chemotherapyinduced peripheral neuropathy: Current status and progress. Gynecol Oncol 2016;140(1):176–83. doi: 10.1016/j.ygyno.2015.11.011
  40. Cavaletti G., Nobile-Orazio E. Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 2007;92(10):1308–10. doi: 10.3324/haematol.11752
  41. Kolb N.A., Smith A.G., Singleton J.R. et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol 2016;73(7):860–6. doi: 10.1001/jamaneurol.2016.0383
  42. Common terminology criteria for adverse events (CTCAE) version 5.0. National Institutes of Health Bethesda, 2017. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
  43. Frigeni B., Piatti M., Lanzani F. et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Periph Nerv Sys 2011;16(3):228–36. doi: 10.1111/j.1529-8027.2011.00351.x
  44. Postma T.J., Aaronson N.K., Heimans J.J. et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005;41(8):1135–9. doi: 10.1016/j.ejca.2005.02.012
  45. Pachman D.R., Qin R., Seisler D.K. et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 2015;33(30):3416. doi: 10.1200/JCO.2014.58.8533
  46. Sun B., Li Y., Liu L. et al. SFN-SIQ, SFNSL and skin biopsy of 55 cases with small fibre involvement. Int J Neurosci 2018;128(5):442–8. doi: 10.1080/00207454.2017.1398152
  47. Lukashenko M.V., Gavrilova N.Y., Bregovskaya A.V. et al. Corneal confocal microscopy in the diagnosis of small fiber neuropathy: faster, easier, and more efficient than skin biopsy? Pathophysiology 2021;29(1):1–8. doi: 10.3390/pathophysiology29010001
  48. Burgess J., Ferdousi M., Gosal D. et al. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Ther 2021;9(2):385–450. doi: 10.1007/s40487-021-00168-y
  49. Thaisetthawatkul P., Fernandes Filho J.A., Herrmann D.N. Contribution of QSART to the diagnosis of small fiber neuropathy. Muscle Nerve 2013;48(6):883–8. doi: 10.1002/mus.23891
  50. Raasing L.R., Vogels O. J., Veltkamp M. et al. Current view of diagnosing small fiber neuropathy. J Neuromusc Dis 2021;8(2):185–207. doi: 10.3233/JND-200490
  51. Terkelsen A.J., Karlsson P., Lauria G. et al. The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol 2017;16(11):934–44. doi: 10.1016/S1474-4422(17)30329-0
  52. Illias A.M., Gist A. C., Zhang H. et al. Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatininduced mechanical hypersensitivity. Pain 2018;159(7):1308. doi: 10.1097/j.pain.0000000000001212
  53. Wang X.M., Lehky T.J., Brell J.M. et al. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012;59(1):3–9. doi: 10.1016/j.cyto.2012.03.027
  54. Fumagalli G., Monza L., Cavaletti G. et al. Neuroinflammatory process involved in different preclinical models of chemotherapyinduced peripheral neuropathy. Front Immunol 2021;11:626687. doi: 10.3389/fimmu.2020.626687
  55. Delaby C., Alcolea D., Carmona-Iragui M. et al. Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep 2020;10(1):1–8. doi: 10.1038/s41598-020-66090-x
  56. Huehnchen P., Schinke C., Bangemann N. et al. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 2022;7(6). doi: 10.1172/jci.insight.154395
  57. Szudy-Szczyrek A., Mlak R., Bury-Kamińska M. et al. Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. Brit J Haematol 2020;191(1):77–89. doi: 10.1111/bjh.16862
  58. De Santis S., Pace A., Bove L. et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 2000;6(1):90–5.
  59. Youk J., Kim Y.S., Lim J.A. et al. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies. PLoS One 2017;12(8):e0183491. doi: 10.1371/journal.pone.0183491
  60. Majithia N., Temkin S.M., Ruddy K.J. et al. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Supp Care Cancer 2016;24(3):1439–47. doi: 10.1007/s00520-015-3063-4
  61. Smith E.M., Pang H., Cirrincione C. et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapyinduced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359–67. doi: 10.1001/jama.2013.2813
  62. Loprinzi C.L., Lacchetti C., Dworkin R.H. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. ASCO 2020. doi: 10.1200/JCO.20.01399

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Тихонова О.А., Дружинин Д.С., Тынтерова А.М., Реверчук И.В., 2023

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 85909 от  25.08.2023.